secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2026-05-14T20:15:18+00:00
Accession:  0001213037-26-000013
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology reports Q1 cash $46.1M, FDA aligns on Phase 3 design for onvansertib
--------------------------------------------------------------------------------

- Cash and investments $46.1M at Q1 end; net cash used $12.3M, runway into Q1 2027.
- Completed End-of-Phase 2 FDA meeting; selected 30 mg onvansertib + FOLFIRI/bev for Phase 3.
- Phase 2 CRDF-004: 30 mg arm ORR 72.2% vs SoC 43.2%; PFS HR 0.38 vs FOLFIRI/bev.
- Appointed Mani Mohindru as permanent CEO, Josh Muntner as CFO, Ajay Aggarwal as COO.
- Updated onvansertib data to be presented at ASCO 2026 rapid oral presentation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000121303726000013/0001213037-26-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000121303726000013/crdf-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001213037-26-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer